Altria Group, Inc. (MO) · Oct 29, 2026 · Earnings
Beat — Adjusted EPS $1.52 vs ~$1.51 consensus
Altria earnings narrowly beat consensus and full-year guidance moved higher, though oral nicotine share and profits continued to deteriorate.
Altria is defending a cash-generative cigarette business while trying to shift consumers toward smoke-free products, especially oral nicotine pouches. The cigarette engine remains profitable through pricing, but the smoke-free transition is not yet producing comparable momentum: the company’s prior-quarter plan already centered on expanding on! PLUS nationally and launching new flavors, while analysts expected roughly $1.51 of Q3 adjusted EPS and about $5.31 billion of revenue.
The quarter was a narrow earnings beat, not a clean operational breakthrough. Adjusted diluted EPS reached $1.52 versus approximately $1.51 consensus, helped by operations, fewer shares and a lower adjusted tax rate. Revenues net of excise taxes rose 3.7% to $5.441 billion, but the business still relied on pricing while shipment volumes declined.
| Metric | Q3 2026 | Q3 2025 | Consensus / prior guide |
|---|---|---|---|
| Adjusted diluted EPS (Table 1) | $1.52 | $1.45 | ~$1.51 consensus |
| Revenues net of excise taxes (Table 2/5) | $5,441M (+3.6%) | $5,250M | ~$5.31B consensus |
| Smokeable adjusted OCI (Table 2) | $3,072M (+3.9%) | $2,956M | |
| Oral adjusted OCI (Table 5) | $443M (-3.7%) | $460M | |
| FY 2026 adjusted EPS guidance | $5.66-$5.74 | $5.42 base | $5.61-$5.72 prior guide |
Pricing is still masking cigarette volume erosion. Smokeable products generated 3.9% adjusted OCI growth and expanded adjusted margins to 64.5%, but domestic cigarette shipment volume fell 2.9%, with Marlboro volume down 6.4%. The mix is also worsening as discount shipments rise sharply, even though total cigarette retail share increased modestly.
The smoke-free transition remains the weak link. Oral tobacco revenue was essentially flat, adjusted OCI fell 3.7%, and adjusted margin contracted 2.8 percentage points to 66.4%. The category is growing—nicotine pouches reached 61.2% of oral tobacco—but on! nicotine-pouch share fell to 13.5%, while total oral tobacco shipment volume dropped 4.3%.
The guidance raise is the clearest new positive. Management lifted the full-year adjusted EPS range from $5.61-$5.72 to $5.66-$5.74, implying confidence that pricing, cigarette import-and-export benefits and operating execution can offset declining volumes. The move is meaningful, but modest: the midpoint rose only 3 cents, and the filing still highlights investment and transition costs.
Bottom line: This was better than expected and the outlook improved, but mostly because the legacy cigarette business continues to monetize pricing power. The core strategic transition remains unresolved as oral nicotine growth is not yet translating into share or profit momentum.
Blueberry Mint and Mango Pineapple retail rollout
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!